Stockreport

Aileron Presents Positive Interim Phase 2a Data for ALRN-6924 in Combination with Pfizer’s Palbociclib at the 2019 Congress of the European Society for Medical Oncology

Aileron Therapeutics, Inc.  (ALRN) 
Last aileron therapeutics, inc. earnings: 11/7 07:30 am Check Earnings Report
US:NASDAQ Investor Relations: investors.aileronrx.com
PDF WATERTOWN, Mass., Sept. 28, 2019 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ: ALRN), the clinical-stage leader in the field of stabilized, cell-permeating peptide [Read more]